Neurology Clinical-Denial Support
A specialty application for neurologic drugs, imaging, procedures, devices, rehabilitation, or level-of-care disputes. It may organize diagnosis and differential, objective findings, disability/function, disease course, treatment failures/intolerance, biomarkers or testing, relapse/activity, contraindications, and…
A bounded clinical support service.
A specialty application for neurologic drugs, imaging, procedures, devices, rehabilitation, or level-of-care disputes. It may organize diagnosis and differential, objective findings, disability/function, disease course, treatment failures/intolerance, biomarkers or testing, relapse/activity, contraindications, and guideline/payer-policy support.
Scope boundary. The client retains filing, portal work, deadlines, signatures, coding, legal strategy, patient care, and any required U.S.-licensed or specialty opinion unless a separate approved scope expressly says otherwise.
The decision problem this service addresses.
Neurologic cases can involve longitudinal disease activity, subtle functional evidence, rare conditions, step therapy, or high-cost treatment pathways. The decisive facts may be distributed across years of records, making chronology and source traceability important.
What the review must resolve.
Disease definition
What diagnosis, subtype, severity, and objective support are documented?
Course and activity
What relapses, progression, episodes, seizures, headaches, or deficits occurred and when?
Treatment pathway
Which therapies were tried, at what dose and duration, with what response or intolerance?
Function
How are mobility, cognition, communication, swallowing, ADLs, work, and safety affected?
Objective evidence
Which imaging, EEG, EMG, laboratory, genetic, CSF, or examination findings matter?
Current request
How do present facts support the exact drug, test, device, procedure, rehabilitation, or setting?
The clinical work product.
- Longitudinal clinical and treatment timeline.
- Evidence map to the client-approved policy/guideline sources.
- Analysis of disease activity, function, treatment failure/intolerance, and exceptions.
- Missing-evidence and risk analysis plus appeal/P2P handoff.
What the client must supply.
Turnaround begins after the agreed record is complete and usable. New records, a different denial rationale, another review period, or a second independent issue can change scope.
- Denial or request and exact service
- Neurology notes, examinations, testing reports, hospitalizations, therapy, and functional records
- Complete treatment history with dose, duration, response, and adverse effects
- Payer policy or authorized criteria
- Prior denials, peer reviews, or appeals for the same pathway
How buyers handle the work today.
- Treating neurologist and specialty pharmacy/PA team.
- Neurology or pharmacy external expert.
- Internal physician advisor/UM team.
- Specialty authorization or denial vendor.
- AI appeal/policy tool.
- Counsel for statutory or contractual access disputes.
The intended role in the workflow.
Clinovian’s useful role is synthesis across a fragmented longitudinal record. It should not claim neurologist equivalence; rare disease, subspecialty devices, or controversial treatment may require an approved specialist.
What the service is designed to prevent.
These are not proof that a denial is wrong. They are ways a potentially supportable case becomes unfocused, overstated, or routed to the wrong capability.
- Relying on a copied diagnosis without current activity or support
- Calling therapy failed without dose, duration, adherence, and reason for stopping
- Ignoring function because the latest examination is stable
- Using an old abnormal test without present relevance
- Forcing a rare case into a generalist conclusion rather than escalating
Market comparison and current Clinovian scope.
No public comparable clinician-review price was found. Enterprise and expert-review services are privately quoted; administrative and AI options are not equivalent. The website’s “auth cycle” dollar range is unsourced and should be removed or replaced by actual client-specific exposure.
Clinovian scope and pricing: Quoted after a de-identified review of longitudinal record length, pathway, and specialist complexity.
Final scope, fixed fee, and turnaround are confirmed before records are transferred; the Engagements & Pricing page remains the public pricing framework.
When to choose it—and when not to.
Choose it when the issue is evidence synthesis and coverage-pathway alignment. Do not choose it when the decision requires a neurologist’s examination, diagnosis, treatment recommendation, licensed sign-off, or rare-disease expertise outside the approved reviewer’s competence.
Send the decision, not the whole account. Fit is confirmed before records.
Provide the denial or request type, payer or plan, review stage, record size, and client-controlled deadline. No PHI is required for the initial scope review.